A spinal cord stimulator is a small device that aids in managing the chronic pain in a better way and to reduce the use of opioid medications. SCS may be used as an option for the people suffering from chronic back, leg or arm pain and when optimum results are not received with other therapies such as medication. It is surgically placed under the skin that transfers mild electric current to the spinal cord. Pulse generator sends current to nerve fibers of the spinal cord by thin wires. After turning on, the SCS stimulates the nerves in the area of pain and reduces the pain as the electrical pulses modify and stop the pain signal from reaching to the brain.
The stimulator does not eradicate the source of pain; however, it interferes with the signal to the brain. Due to this, the relief from pain varies from patient to patient. Sometimes patients feel a tingling sensation, which is unpleasant; as a result of this, trial stimulation is performed before the permanent implantation. 50-70% reduction in pain can be achieved by the implantation.
Some of the major companies working in the field of SCS include Abbott Laboratories Incorporated, Boston Scientific Corporation, Cala Health, Incorporated, Livanova PLC, Medtronic PLC, Nevro Corporation, Nuvectra Corporation, Stimwave LLC, among others. Major focus of the market players includes R&D and product launch. For instance, in January 2019, Boston Scientific Corporation had launched Spectra WaveWriter SCS System in Europe. It can treat chronic pain as per individual needs by simultaneously combining paresthesia-based and sub-perception therapy. By this, physicians can customize therapy and capture real-time feedback of the device.
In January 2018, Nevro Corporation received the US FDA approval for its next-generation Senza II SCS System delivering HF10 therapy. It provides better results of HF10 therapy by a smaller and more refined footprint compared to its conventional products. In June 2019, Nuvectra Corporation filed for expanded the US FDA approval of its Algovita SCS device. The company needs approval for full-body MR-conditional for the Algovita SCS. The device has already received the US FDA premarket approval in 2015. The US FDA has classified most of the neurostimulators into class II, and class III products.
The Report Covers
- Comprehensive research methodology of the Spinal cord Stimulators market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Spinal cord Stimulators Market.
- Insights about market determinants which are stimulating the Spinal cord Stimulators Market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
Key Topics Covered:
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
3.1. Competitive Dashboard
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
5. Market Segmentation
5.1. Global Spinal cord Stimulators Market by Applications
5.1.1. Failed Back Syndrome
5.1.2. Complex Regional Pain Syndrome
5.1.3. Degenerative Disk Disease
5.2. Global Spinal cord Stimulators Market by End-Users
5.2.1. Hospitals and Clinics
5.2.2. Research Institutes
5.3. Regional Analysis
5.4. North America
5.4.1. United States
5.5.6. Rest of Europe
5.6.4. Rest of Asia-Pacific
5.7. Rest of the World
6. Company Profiles
6.1. BioControl Medical Inc.
6.2. Boston Scientific Corp.
6.3. Cyberonics Inc.
6.4. Medtronic, Inc.
6.5. Neuronetics Inc.
6.6. Neuropace Inc.
6.7. Neurosigma Inc.
6.8. Nevro Corp.
6.9. Nuvectra Corp.
6.10. St. Jude Medical Inc.
6.11. Synapse Biomedical Inc.
For more information about this report visit https://www.researchandmarkets.com/r/xqyfm3